Literature DB >> 32717116

COVID-19 and implications for dermatological and allergological diseases.

Timo Buhl1,2, Stefan Beissert3, Evelyn Gaffal4, Matthias Goebeler5, Michael Hertl6, Cornelia Mauch7, Kristian Reich8, Enno Schmidt9,10, Michael P Schön1,2, Michael Sticherling11, Cord Sunderkötter12, Claudia Traidl-Hoffmann13,14, Thomas Werfel15, Dagmar Wilsman-Theis16, Margitta Worm17.   

Abstract

COVID-19, caused by the coronavirus SARS-CoV-2, has become pandemic. A further level of complexity opens up as soon as we look at diseases whose pathogenesis and therapy involve different immunological signaling pathways, which are potentially affected by COVID-19. Medical treatments must often be reassessed and questioned in connection with this infection. This article summarizes the current knowledge of COVID-19 in the light of major dermatological and allergological diseases. It identifies medical areas lacking sufficient data and draws conclusions for the management of our patients during the pandemic. We focus on common chronic inflammatory skin diseases with complex immunological pathogenesis: psoriasis, eczema including atopic dermatitis, type I allergies, autoimmune blistering and inflammatory connective tissue diseases, vasculitis, and skin cancers. Since several other inflammatory skin diseases display related or comparable immunological reactions, clustering of the various inflammatory dermatoses into different disease patterns may help with therapeutic decisions. Thus, following these patterns of skin inflammation, our review may supply treatment recommendations and thoughtful considerations for disease management even beyond the most frequent diseases discussed here.
© 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.

Entities:  

Year:  2020        PMID: 32717116     DOI: 10.1111/ddg.14195

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  5 in total

Review 1. 

Authors:  Oliver Pfaar; Ludger Klimek; Eckard Hamelmann; Jörg Kleine-Tebbe; Christian Taube; Martin Wagenmann; Thomas Werfel; Randolf Brehler; Natalija Novak; Norbert K Mülleneisen; Sven Becker; Margitta Worm
Journal:  Allergo J       Date:  2021-08-13

2.  COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA).

Authors:  Oliver Pfaar; Ludger Klimek; Eckard Hamelmann; Jörg Kleine-Tebbe; Christian Taube; Martin Wagenmann; Thomas Werfel; Randolf Brehler; Natalija Novak; Norbert Mülleneisen; Sven Becker; Margitta Worm
Journal:  Allergol Select       Date:  2021-04-01

3.  The Impact of COVID-19 Pandemic on Medical Doctors' Work-Family Balance at German University Clinics.

Authors:  Caroline Beutner; Anja Lipschik; Luise Erpenbeck; Jason Holsapple; Michael P Schön; Hedwig Stanisz
Journal:  Healthcare (Basel)       Date:  2022-01-25

4.  The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics

Authors:  Imke Nordhorn; Daniela Weiss; Thomas Werfel; Alexander Zink; Maximilian C Schielein; Stephan Traidl
Journal:  Eur J Dermatol       Date:  2022-04-01       Impact factor: 2.805

5.  The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients.

Authors:  Martyna Miodońska; Agnieszka Bogacz; Magdalena Mróz; Szymon Mućka; Andrzej Bożek
Journal:  Medicina (Kaunas)       Date:  2021-05-22       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.